XML 45 R35.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Geneos Therapeutics, Inc. (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Noncontrolling Interest [Abstract] |
Schedule of Equity Method Investments | The Company recorded its current and accumulated share of net losses of Geneos of $2.2 million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:
Investment in Geneos Series A-2 preferred stock |  | $ | 1,999,998 |
Remeasurement of Geneos Series A-1 preferred stock |  | 165,215 |
Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022 |  | (2,165,213) |
Investment in Geneos as of March 31, 2022 |  | $ | — |

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_NoncontrollingInterestAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration